Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C18H26O3 |
Molecular Weight | 290.3972 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 6 / 6 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]3([H])[C@@]4([H])CCC(=O)C(O)=C4CC[C@@]23[H]
InChI
InChIKey=GXHBCWCMYVTJOW-YGRHGMIBSA-N
InChI=1S/C18H26O3/c1-18-9-8-11-10-4-6-15(19)17(21)13(10)3-2-12(11)14(18)5-7-16(18)20/h10-12,14,16,20-21H,2-9H2,1H3/t10-,11-,12-,14+,16+,18+/m1/s1
DescriptionCurator's Comment: Description was created based on several sources, including http://pilarmartinescudero.es/EneroFebreroMarzo2014/capillary_investigation_oxabolone_man.pdf and http://www.basskilleronline.com/profile-steranabol.shtml
Curator's Comment: Description was created based on several sources, including http://pilarmartinescudero.es/EneroFebreroMarzo2014/capillary_investigation_oxabolone_man.pdf and http://www.basskilleronline.com/profile-steranabol.shtml
Oxabolone is a synthetic anabolic steroid. It can be formulated as the cipionate ester prodrug oxabolone cipionate. Oxabolone cypionate is a structural derivative of nandrolone. It differs via the additional 4-hydroxyl group that is attached, therefore making oxabolone cypionate 4-hydroxynandrolone. Oxabolone is on the World Anti-Doping Agency's list of prohibited substances, and is therefore banned from use in most major sports. Oxabolone cypionate is a relatively rare drug that was once produced in Europe for human use. Was used for the treatment of osteoporosis. It is no longer produced by pharmaceutical companies; Upjohn and Pharmacia were the primary producers of it previously.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL1871 Sources: http://www.kegg.jp/entry/D01149 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Palliative | Unknown Approved UseUnknown |
|||
Sources: http://www.ndrugs.com/?s=steranabol |
Primary | Steranabol Approved UseIndications: anabolic, osteoporosis, diabetic retinopathy |
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
DEA NO. |
4000
Created by
admin on Fri Dec 15 20:11:19 GMT 2023 , Edited by admin on Fri Dec 15 20:11:19 GMT 2023
|
||
|
WHO-ATC |
A14AB03
Created by
admin on Fri Dec 15 20:11:19 GMT 2023 , Edited by admin on Fri Dec 15 20:11:19 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
225-212-2
Created by
admin on Fri Dec 15 20:11:19 GMT 2023 , Edited by admin on Fri Dec 15 20:11:19 GMT 2023
|
PRIMARY | |||
|
m379
Created by
admin on Fri Dec 15 20:11:19 GMT 2023 , Edited by admin on Fri Dec 15 20:11:19 GMT 2023
|
PRIMARY | Merck Index | ||
|
20055236
Created by
admin on Fri Dec 15 20:11:19 GMT 2023 , Edited by admin on Fri Dec 15 20:11:19 GMT 2023
|
PRIMARY | |||
|
DTXSID50878357
Created by
admin on Fri Dec 15 20:11:19 GMT 2023 , Edited by admin on Fri Dec 15 20:11:19 GMT 2023
|
PRIMARY | |||
|
DB01500
Created by
admin on Fri Dec 15 20:11:19 GMT 2023 , Edited by admin on Fri Dec 15 20:11:19 GMT 2023
|
PRIMARY | |||
|
OXABOLONE
Created by
admin on Fri Dec 15 20:11:19 GMT 2023 , Edited by admin on Fri Dec 15 20:11:19 GMT 2023
|
PRIMARY | |||
|
51RPF719WE
Created by
admin on Fri Dec 15 20:11:19 GMT 2023 , Edited by admin on Fri Dec 15 20:11:19 GMT 2023
|
PRIMARY | |||
|
3802
Created by
admin on Fri Dec 15 20:11:19 GMT 2023 , Edited by admin on Fri Dec 15 20:11:19 GMT 2023
|
PRIMARY | |||
|
4721-69-1
Created by
admin on Fri Dec 15 20:11:19 GMT 2023 , Edited by admin on Fri Dec 15 20:11:19 GMT 2023
|
PRIMARY |
ACTIVE MOIETY